ADCT
ADC Therapeutics SA
1.20$
+9.8%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| – | +75.4% | -44.6% | -8.6% | +273.1% | +20.3% | -20.6% | -27.7% | -9.2% | +0.4% | |
| – | +75.3% | -46.4% | -13.7% | +267.4% | +16.6% | -17.2% | -22.7% | -8.6% | -0.3% | |
| – | +82.9% | -47.2% | -16.8% | +280.1% | +6.2% | -30.0% | -14.7% | -10.0% | +4.2% | |
| – | +82.9% | -47.2% | -16.8% | +280.1% | +6.2% | -30.0% | -14.7% | -10.0% | +4.2% | |
| – | -67.4% | -80.7% | +663.4% | -5.3% | +1,054.6% | +134.9% | -65.5% | -19.3% | +43.3% | |
| – | – | +310.9% | +105.3% | +162.9% | +71.1% | +8.6% | +34.0% | +13.7% | -77.2% | |
| – | – | +34.9% | +307.4% | -24.2% | +136.0% | -11.1% | – | – | – | |
| – | +85.4% | +23.6% | +26.4% | +20.7% | +33.4% | +5.7% | – | – | – | |
| – | +60.6% | +6.7% | +9.1% | +571.7% | +153.6% | -9.0% | +22.3% | +4.3% | -3.0% | |
| – | +112.5% | +8.8% | -10.8% | +102.8% | +82.8% | +10.8% | -17.4% | +18.9% | -12.8% | |
| – | – | – | – | +309.3% | +64.1% | +78.5% | -89.2% | -6.5% | +118.8% | |
| – | +255.2% | -11.4% | -50.7% | +58.6% | +128.8% | +2.2% | +26.1% | +15.8% | -49.1% | |
| – | – | – | – | – | +15.9% | -22.3% | +15.9% | +0.8% | -1.0% | |
| – | +76.8% | -49.3% | -12.0% | +201.8% | -50.5% | -52.2% | -286.6% | – | – | |
| – | – | – | – | – | – | – | – | – | – | |
| – | – | -8.5% | +24.2% | -2.2% | +17.3% | +1.8% | +4.6% | +18.9% | +30.8% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.